Fischer-Riepe L*, Kailayangiri S*, Zimmermann K*, Pfeifer R*, Aigner M*, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A*, Jungblut M*, Schambach A*, Abken H*, Rossig C*. *Have contributed equally. Preclinical development of CAR T cells with antigen-inducible IL-18 enforcement to treat GD2-positive solid cancers. Clin Cancer Res, accepted for publication. (IF 13.801)

Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, del Bufalo F, Rives S, Jacoby E, Balduzzi A, Bourquin JP, Baruchel A. CAR T cell products for pediatric cancers: Why alternative development paths are needed. J Clin Oncol. 2024 Jan 20;42(3):253-257. doi: 10.1200/JCO.23.01314 (IF 45.3)

Altvater B*, Kailayangiri S*, Spurny C, Flügge M, Meltzer J, Greune L, Urban K, Schwöppe, C, Brand C, Schliemann C, Hintelmann H, Harrach S, Hartmann W, Abken H, Kuehle J, Schambach A, Görlich G, Berdel WE*, Rossig C* (* contributed equally). CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process. Cancer Gene Ther 2023, https://doi.org/10.1038/s41417-023-00642-x (IF 5.854)

Meissner, R., Wixler, V., Wulfert, F.P., Jacob, J.C., Hale, B.G., Robeck, T., Masemann, D., Boergeling, Y., and Ludwig, S. (2023). Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer. Mol Ther Oncolytics 31, 100741. 10.1016/j.omto.2023.100741.

Pearson ADJ*, Rossig C*, Mackall C*, Shah NN*, Baruchel A*, et al. *Joint first authors. Paediatric Strategy Forum for Medicinal Product Development of CAR T-cells in children and adolescents with cancer. ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022 Jan;160:112-133 (IF 9.162)

Altvater B, Kailayangiri S, Pérez Lanuza LF, Urban K, Greune L, Flügge M, Meltzer J, Farwick N, König S, Görlich D, Hartmann W, Rossig C. HLA-G and HLA-E immune checkpoints are widely expressed in Ewing sarcoma but have limited functional impact on the effector functions of antigen-specific CAR T cells. Cancers 2021;13(12):2857 (IF 6.639)

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C. EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells. Mol Ther 2019;27(5):933-946

Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Meltzer J, Farwick N, Greune L, Rossig C. Targeting Ewing sarcoma with activated and GD2-specific chimeric receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology 2016;6(1):e1250050 (IF 7.719)

Claudia Rössig

Contact details

Publications